Terlivaz finally brought terlipressin to the American market, where clinicians had long relied on off-label vasoconstrictor combinations for hepatorenal syndrome while it was standard elsewhere.
As a vasopressin V1 receptor agonist, it constricts splanchnic blood vessels to raise effective arterial volume and restore perfusion to the kidneys. The intravenous therapy improves kidney function in adults with hepatorenal syndrome accompanied by rapid reduction in kidney function.
Terlivaz is the first FDA-approved therapy for the condition and holds orphan designation with no generic competition. Its label carries a boxed warning for serious or fatal respiratory failure, which shapes patient selection and is the main constraint on broader use.
